CORCEPT THERAPEUTICS INC. overview

MENLO PARK, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol, today announced that Atabak Mokari has joined the company as Chief Financial Officer. Charles Robb, who has been Corcept’s CFO since September 2011, has assumed the role of Chief Business Officer....

2020 revenue of $353.9 million, compared to $306.5 million in 2019 Fourth quarter revenue of $85.7 million, compared to $87.9 million in 2019 2020 GAAP net income of $106.0 million, compared to $94.2 million in 2019 Fourth quarter GAAP net income of $26.0 million, compared to $29.4 million in fourth quarter 2019 Cash and investments of $476.9 million at year-end, compared to $315.3 million at year-end 2019 Acquisition of 458,769 shares pursuant to the company’s stock repurchase program...

Financial Highlights, 2021 Revenue Guidance and Legal Update Preliminary 2020 revenue $353.9 million, compared to $306.5 million in 2019 Preliminary fourth quarter revenue $85.7 million, compared to $87.9 million in fourth quarter 2019 2021 revenue guidance $375 - 405 million Preliminary 2020 fully diluted GAAP net income $0.85 per share, compared to $0.77 per share in 2019 Preliminary fourth quarter fully diluted GAAP net income $0.20 per share, compared to $0.24 per share in fourth quarter...

MENLO PARK, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its preliminary 2020 fourth quarter and full-year financial results and provide a corporate update on February 8, 2021. The company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information To participate, dial 1-833-693-0540 (United States) or 1-661-407-1581 (internationally) approximately 15 minutes...

MENLO PARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that Gillian M. Cannon, PhD, has joined the company’s Board of Directors. Dr. Cannon brings to Corcept more than 30 years experience in the pharmaceutical industry, where she has...

MENLO PARK, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, announced today that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued a decision upholding the validity of all claims of U.S. Patent No. 10,195,214,...

MENLO PARK, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today reported its results for the quarter ended September 30, 2020. Financial Highlights Revenue of $86.3 million, a 6 percent increase from third quarter 2019 GAAP diluted net income of $0.17 per...

MENLO PARK, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 3, 2020. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information To participate, click the link below and enter your information. The link will become active 15 minutes prior to the scheduled start time. Click to...

SHAREHOLDER ALERT: Kaskela Law LLC Announces Stockholder Investigation of Corcept Therapeutics Incorporated (CORT) and Encourages Long-Term CORT Stockholders to Contact the Firm PR Newswire PHILADELPHIA, Sept. 29, 2020 PHILADELPHIA , Sept. 29, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT) on behalf of the company's stockholders. Recently, an amended securities fraud complaint was filed against...

MENLO PARK, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced enrollment of its first patient in GRATITUDE II, a randomized, double-blind, placebo-controlled, Phase 2 trial of miricorilant in obese patients with schizophrenia and long-standing...

...

MENLO PARK, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today reported its results for the quarter ended June 30, 2020. Financial Highlights Revenue of $88.6 million, a 23 percent increase from second quarter 2019 GAAP diluted net income of $0.23 per...

MENLO PARK, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update on August 4, 2020. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information To participate, dial 1-800-353-6461 from the United States or 1-334-323-0501 internationally approximately ten minutes before the start of the call....

MENLO PARK, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced enrollment of its first patient in GRADIENT, a double-blind, placebo-controlled, Phase 3 trial of relacorilant in patients with Cushing’s syndrome caused by adrenal adenomas or hyperplasia. “We are...

MENLO PARK, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced the completion of enrollment in its controlled, Phase 2 trial of relacorilant combined with nab-paclitaxel (Abraxane ® ) in patients with metastatic, platinum-resistant ovarian cancer. “We achieved...